MicroPort® and Shanghai East Hospital Establish Translational Medicine Joint Research Center

Shanghai, China – On July 8, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") singed a strategic agreement with Shanghai East Hospital of Tongji University School of Medicine to jointly establish "Shanghai East Hospital – MicroPort® Translational Medicine Joint Research Center" and carry out comprehensive cooperation in cardiovascular diseases, cardiac failure, cardiac surgery, cerebrovascular diseases, and comprehensive diagnosis and treatment of tumors.
Shanghai East Hospital is a large-scale top hospital in China integrating medical treatment, academic education, scientific research, emergency service, and healthcare, covering 10 key subjects of Shanghai and China, and is specialized in cardiac failure treatment, cardiac surgery, cardiovascular diseases treatment, and comprehensive diagnosis and treatment of tumors. Based on the win-win principle, this strategic partnership between MicroPort® and Shanghai East Hospital leverages complementary strengths and resources of the two respected parties in the industry. By jointly establishing the translational medicine joint research center, MicroPort® and Shanghai East Hospital will focus on developing innovative medical devices, applying minimally invasive surgery technologies, cultivating medical talents, and launching academic workshops and exchange programs.
During the signing ceremony, MicroPort® Chief Technology Officer Dr. Qiyi Luo shared the major measures and advancement of MicroPort®'s innovative path. Afterwards, the two parties had in-depth discussions related with the areas of their cooperation, paving the way for the following collaboration. Zhongmin Liu, President of Shanghai East Hospital, highly recognized MicroPort®'s contribution to the development of China's high-end medical device industry, and encouraged representatives of the two parties to live up to the agreement to increase the momentum for innovation in China's medical device industry.
Dr. Zhaohua Chang, MicroPort® Chief Executive Officer, stated: "MicroPort® always places priority on product R&D and independent innovation, in particular, clinical-needs-oriented R&D collaborations. In fact, several MicroPort® high-end products are the fruits of close cooperation between R&D engineers and clinicians. We hope this strategic agreement will allow R&D engineers of MicroPort® and clinicians of Shanghai East Hospital to team up for revolutionary innovations, so as to drive the development of China's medical science and to benefit patients in China and worldwide."